Norepinephrine + Ascorbic Acid for Cardiovascular Risk

Phase-Based Progress Estimates
1
Effectiveness
1
Safety
Cardiovascular Risk+2 MoreNorepinephrine + L-NAME + Ascorbic Acid - Drug
Eligibility
18 - 35
All Sexes
What conditions do you have?
Select

Study Summary

This study is evaluating whether a drug may help improve blood flow in the skin of black individuals.

Eligible Conditions
  • Cardiovascular Risk
  • Vasoconstriction
  • Cardiovascular Disease

Treatment Effectiveness

Effectiveness Progress

1 of 3

Similar Trials

1
Circadian Study Protocol
1
Ascorbic acid
1
Hypoxia Exposure

Study Objectives

2 Primary · 0 Secondary · Reporting Duration: Through study completion, an average of 1 Year

Year 1
Role of Oxidative Stress in Heightened Vasoconstriction using Laser Doppler Fluxmetry
Vasoconstrictor Responsiveness to Norepinephrine using Laser Doppler Fluxmetry

Trial Safety

Safety Progress

1 of 3

Similar Trials

1
Circadian Study Protocol
1
Ascorbic acid
1
Hypoxia Exposure

Trial Design

4 Treatment Groups

Control (Norepinephrine)
1 of 4
Norepinephrine + Ascorbic Acid
1 of 4
Norepinephrine + L-NAME + Ascorbic Acid
1 of 4
Norepinephrine + L-NAME
1 of 4

Active Control

Experimental Treatment

50 Total Participants · 4 Treatment Groups

Primary Treatment: Norepinephrine + Ascorbic Acid · No Placebo Group · Phase 1

Norepinephrine + Ascorbic Acid
Drug
Experimental Group · 1 Intervention: Norepinephrine + Ascorbic Acid · Intervention Types: Drug
Norepinephrine + L-NAME + Ascorbic Acid
Drug
Experimental Group · 1 Intervention: Norepinephrine + L-NAME + Ascorbic Acid · Intervention Types: Drug
Norepinephrine + L-NAME
Drug
Experimental Group · 1 Intervention: Norepinephrine + L-NAME · Intervention Types: Drug
Control (Norepinephrine)
Drug
ActiveComparator Group · 1 Intervention: Control (Norepinephrine) · Intervention Types: Drug

Trial Logistics

Logistics

Participation is compensated

You will be compensated for participating in this trial.

Trial Timeline

Screening: ~3 weeks
Treatment: Varies
Reporting: through study completion, an average of 1 year

Who is running the clinical trial?

The University of Texas at ArlingtonLead Sponsor
25 Previous Clinical Trials
2,363 Total Patients Enrolled
4 Trials studying Cardiovascular Risk
134 Patients Enrolled for Cardiovascular Risk

Eligibility Criteria

Age 18 - 35 · All Participants · 2 Total Inclusion Criteria

Mark “Yes” if the following statements are true for you:
References

Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Back to top